Suppr超能文献

依赖类固醇的哮喘患者对雾化吸入倍氯米松和口服泼尼松的最小剂量需求。

Minimum dose requirements of steroid-dependent asthmatic patients for aerosol beclomethasone and oral prednisone.

作者信息

Toogood J H, Lefcoe N M, Haines D S, Chuang L, Jennings B, Errington N, Baksh L, Cauchi M

出版信息

J Allergy Clin Immunol. 1978 Jun;61(6):355-64. doi: 10.1016/0091-6749(78)90114-8.

Abstract

In 34 steroid-dependent asthma patients who improved markedly during 2 mo of treatment when progressively larger doses of beclomethasone aerosol were added to their oral prednisone regimen, we subsequently reduced both steroids to ascertain the minimum dose of each needed to prevent recurrence of significant asthmatic disability. After 80 wk of follow-up, 15 patients had successfully terminated oral prednisone; 19 were better controlled with a combination of aerosol plus oral steroid than with either drug alone; all patients previously unable to convert to alternate-day prednisone did so successfully during the combined therapy. The minimum effective maintenance dosage varied greatly among these patients-the median values being 2.5 mg prednisone and 1,200 microgram beclomethasone per day. The latter ranged from 200 to 1,8000 microgram. Only 4 patients were satisfactorily controlled without prednisone on 400 microgram beclomethasone per day or less. Seven needed extra intranasal beclomethasone to help control the nasal polyps which worsened after prednisone withdrawal. Suppression of plasma cortisol levels, apparently attributable to the beclomethasone, persisted in most patients, but on the average this was no worse than before commencing this treatment and valuable clinical improvement accrued. There were no other important complications of the regimen. In most of these patients with severe chronic asthma, optimum control of the disease required combined aerosol-oral therapy and maintenance doses of beclomethasone higher than those usually recommended. In some patients, effective control of chronic asthma by beclomethasone treatment may require acceptance of some persisting suppression of adrenal function as a considered risk.

摘要

在34例类固醇依赖型哮喘患者中,在其口服泼尼松治疗方案基础上逐渐增加倍氯米松气雾剂剂量,治疗2个月后病情显著改善。随后,我们减少两种类固醇药物剂量,以确定预防哮喘严重失能复发所需的每种药物的最小剂量。经过80周的随访,15例患者成功停用口服泼尼松;19例患者联合使用气雾剂加口服类固醇比单独使用任何一种药物时病情控制得更好;所有先前无法改为隔日服用泼尼松的患者在联合治疗期间均成功实现。这些患者的最小有效维持剂量差异很大,泼尼松的中位数为每日2.5毫克,倍氯米松为每日1200微克。后者的范围为200至18000微克。只有4例患者每日服用400微克或更少的倍氯米松且未使用泼尼松时病情得到满意控制。7例患者需要额外的鼻内倍氯米松来帮助控制泼尼松撤药后恶化的鼻息肉。大多数患者血浆皮质醇水平的抑制显然归因于倍氯米松,但平均而言,这并不比开始这种治疗前更严重,且取得了有价值的临床改善。该治疗方案没有其他重要并发症。在大多数这些严重慢性哮喘患者中,疾病的最佳控制需要联合气雾剂-口服治疗,且倍氯米松的维持剂量高于通常推荐的剂量。在一些患者中,通过倍氯米松治疗有效控制慢性哮喘可能需要接受肾上腺功能的一些持续抑制作为一种可接受的风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验